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Amyotrophic Lateral Sclerosis (ALS)
Amber Stewart RN, BSN
Otterbein University, Westerville, Ohio

ALS
•

Degenerative disease of upper and
lower motors neurons.

•

Between 20,000-30,000 Americans
currently living with the disease
(Bellomo & Chichminski, 2015).

•

•

•

•

•

•

Estimated 5,000 new cases
diagnosed each year (Bellomo &
Chichminski, 2015).

•

Muscle twitching, or fasciculation

•

Muscle weakness

•

Hyperreflexia

•

Positive Babinski and Hoffman
signs

•

Emotional lability

Affects whites more than any other
ethnic group in the United States
(Rechtman, Jordan, Wagner,
Horton, & Kaye 2015).

•

Usually begins in the arms in
2/3rds of patients

•

Foot drop

Typically affects males more than
females. Males often have a longer
prognosis as well as those
diagnosed younger in life, and those
with limb onset versus bulbar onset
(Rechtman et al, 2015).

•

Difficulty walking

•

Loss of hand dexterity

•

Weakness when lifting arms
(Gordon, 2013).

Prognosis after diagnosis averages
three to five years (Bellomo &
Chichminski, 2015).

•

80% present with asymmetric limb
weakness

Most common cause of death is
respiratory muscle weakness
(Gordon, 2013).
There is no cure, only palliative
support (Gordon, 2013).

Why should
clinicians care?
●Over the past 10 years there has been
no progress in the time it takes for
clinicians to recognize and diagnose ALS.
The average time from symptom onset to
diagnosis is still eight to 16 months. This
delay in diagnosis delays the patient and
caregivers’ access to critical supportive
measures.
●Misdiagnosis could potentially cause
increase in suffering as unnecessary
testing or surgeries might be performed.
●Patients receiving care for ALS from a
multidisciplinary team report higher
quality of life.(Williams, Fitzhenry, Grant,
Martyn, & Kerr, 2013).

•

•

20% present with bulbar onset
•
Dysarthia
•
Dysphagia
There is no single definitive test.
ALS is diagnosed by ruling out
other diseases and the presenting
signs and symptoms (Bellomo &
Chichminski, 2015).

•

Demyelination of upper and lower
motor neurons.

•

Loss of myelinated axons in the
lateral and anterior columns of the
spinal cord.

•

Decrease in the size of the anterior
horn in the spinal cord.

•

Degeneration and loss of large
motor neurons in the anterior horn
of the spinal cord, lower cranial
motor nuclei of the brainstem, and
Betz cells in the motor cortex.

•

Global reduction of all neurons in
the anterior horn.

•

Reduction of neuron size as well as
atrophy of nerve fibers in ALS.

•

Large empty spaces occur near
neurons.

•

Microscopic holes , which create a
sponge-like appearance also occur.

•

Bunina bodies are found in ALS,
these are small (3-6microns big )
eosinophilic inclusions that are
found in cytoplasm of motor
neurons. Their significance is not
understood (Saberi, Stauffer,
Schulte, & Ravits, 2015).

Familial ALS

Pathophysiology Continued

Pathophysiology

Signs & Symptoms

Reactive astrocytes display
increased immunoreactivity for the
proteins GFAP and S100B. They
express inflammatory markers, like
COX -2, neuronal NOS (Saberi et al,
2015).

•

•

TDP-43 is a ribonucleic protein that
stabilizes mRNA, and assists with its
processing, transport, and
translocation (Saberi et al, 2015).

•

In those with ALS, there is a loss of
function in TDP-43 and noted
formation of pathological
aggregates, like ubiquitin, in the
cytoplasm of the cells (Saberi et al,
2015).

Microglia are activated in response
to neuronal distress and release
proinflammatory cytokines and
reactive oxygen species as a result
(Saberi et al, 2015).

•

Ubiquitin, a dense, round structure
found in the cytoplasm of neurons
in the anterior horn cells, is
indicative of ALS (Saberi et al,
2015).
Picture retrieved from Picher-Martel,
Vladmanis, Gould, Julien, & Dupre,
( 2016).

•

The morphology of cell death in ALS
in not clearly understood, but
research points to cell apoptosis
(Saberi et al, 2015).

•

Axonal regrowth is inhibited by a
pathological protein found in
muscles fibers called NOGO-A
(Gordon, 2013).

•

•

Superoxide dismutase-1 (SOD1)
mutations accounts for 20% of
familial ALS (fALS). (Saberi et al,
2015)

•

SOD1 has deposition of
ubiquitinated TDP-43 negative
SOD1 proteins in neurons of cells
(Gordon, 2013).

•

SOD1 has younger average age for
onset, predominately starts in the
legs with lower motor neuron
disturbances, and has low
occurrence of cognitive
disturbances (Gordon, 2013).

•

TARDBP mutations account for 5%
of fALS cases (Gordon, 2013).

•

TARDBP gene causes TDP-43
positive inclusions in the brain
which leads to defects in RNA
processing (Gordon, 2013).

•

Whites with TARDBP often have
onset of ALS in the arm while
Asians with this mutation often
have bulbar onset and longer
disease duration (Gordon,2013).

•

FUS mutations make up 5% of
fALS, and affects amino acids in the
FUS gene (Gordon, 2013).

•

FUD mutations lead to onset of ALS
at ages less than 40 in one third of
the cases, typically present in the
arms, and survival time is typically
less than two years (Gordon, 2013).

•

c9ORF72 is the most frequently
occurring gene mutation in fALS,
accounting for up 40% of cases
(Gordon, 2013).

•

TDP-43 accumulation in the brain
and deposits of p62 show up
predominately in c9ORF72
(Gordon, 2013).

Representation retrieved from beatalsbenefit.com (2018)

Sporadic ALS
•

Sporadic ALS occurs in 90% of all
cases (Saberi et al, 2015)

•

Increased age, cigarette smoking,
and pesticide exposure, service in
the first Gulf War, and high levels of
athleticism have been linked to
increased risk for ALS. Trauma also
shows an associative link. (Gordon,
2013).

There is very little difference in disease
signs and symptoms, progression, or
prognosis in sporadic v. familial ALS. There
is no cure for either variation, and all
measures are supportive.

Significance of
Pathophysiology
Because ALS affects upper and lower
motor neuron function, it eventually
affects the entire body. The affected
person may start out needing minimal
help with activities of daily living (ADL),
but eventually, loss of motor neuron
function impairs body muscle movement
to the point that the affected person is
completely dependent on others for all
ADLs
The most common complication
leading to death is respiratory failure.
Some affected by the disease may choose
to initiate life prolonging measures such
as placement of a PEGG or intubation and
ventilation, but others may seek
palliative care earlier on. Since there is
no cure for ALS, and only one drug
available on the market that has been
shown to slow disease progression
minimally, getting multiple supportive
services into the home early has been
proven to provide great benefit to the
affected person and their loved ones
through greater quality and quantity of
life. (Williams et al., 2013)

Conclusion
Amyotrophic lateral sclerosis is a
disease characterized by the
demyelination of upper and lower
motor neurons. This may start
locally, in the arm or leg, or could
start with bulbar presentation, but
eventually spreads to affect the
entire body.
Most cases of ALS are sporadic,
but up to 10% can have a genetic
component. More research is needed
in both types of ALS to help the
medical field better understand and
treat the disease.
There is no known cure for ALS.
All treatment is supportive in nature
with an important focus on a
multidisciplinary approach to
support patients and their families.
Prognosis after diagnosis is most
commonly three to five years, but
can be longer or shorter. Getting a
quick diagnosis and supportive
resources in sooner has been shown
to have better patient reports of
quality of life as well as longer
prognosis.

Implications in
Nursing

The implications of caring for
someone with a life limiting and
incurable disease shift the focus to
supportive measures such as diet,
respiratory therapy, home medical
equipment, physical therapy, or
counseling.
Ensuring that nursing care focuses
on comfort, aligns with the patient and
family’s goals of care, and employs a
multidisciplinary approach is key.
Nurses need to use their resources and
make referrals as appropriate.
Nurses will also need to be vigilant
in assessing for skin breakdown for the
bedbound and nutritionally impaired,
assessing for respiratory infections and
encouraging good pulmonary habits,
and guiding patients and family’s on
food choices and safe swallowing
techniques as dysphagia presents itself.
Communication in later stages of
ALS can become problematic for many
patients. Coming up with creative ways
to communicate and encouraging early
discussions about what a person wants
for their future care will help guide
families and clinicians alike through the
terminal stages of the disease.
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